Comparative Pharmacology
Head-to-head clinical analysis: OPTIRAY 240 versus OPTIRAY 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIRAY 240 versus OPTIRAY 350.
OPTIRAY 240 vs OPTIRAY 350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OPTIRAY 240 (ioversol) is a nonionic, iodinated, water-soluble radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during imaging procedures. Its mechanism is physical: the iodine atoms absorb X-rays, providing radiopacity.
Iodinated radiocontrast agent that attenuates X-rays and enhances visualization of vascular structures and organs during imaging procedures.
Intravenous administration: 50-150 mL of OPTIRAY 240 (iopamidol 240 mg iodine/mL) for adult computed tomography (CT) imaging, typically as a bolus or rapid infusion. Dose depends on procedure and patient size.
Intravenous administration: 50-150 mL of 350 mgI/mL solution for contrast-enhanced CT; dose determined by procedure, body weight, and clinical indication. Intra-arterial: Varies per procedure, typically 30-60 mL total. Maximum single dose not established; avoid exceeding 5 mL/kg body weight.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours in patients with normal renal function; prolonged in renal impairment (up to 30 hours in severe impairment).
2.0 ± 0.4 hours in patients with normal renal function (creatinine clearance >90 mL/min); prolonged to 10-40 hours in severe renal impairment (CrCl <30 mL/min)
Primarily renal (glomerular filtration); >90% of administered dose excreted unchanged in urine within 24 hours; <1% biliary/fecal.
Renal: 90-95% as unchanged drug via glomerular filtration within 24 hours; biliary/fecal: <5%
Category C
Category C
Radiological Contrast Agent
Radiological Contrast Agent